RhumbLine Advisers’s IDEAYA Biosciences IDYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.76M | Buy |
131,149
+6,712
| +5% | +$141K | ﹤0.01% | 1710 |
|
|
2025
Q1 | $2.04M | Buy |
124,437
+10,876
| +10% | +$178K | ﹤0.01% | 1800 |
|
|
2024
Q4 | $2.92M | Buy |
113,561
+585
| +0.5% | +$15K | ﹤0.01% | 1694 |
|
|
2024
Q3 | $3.58M | Buy |
112,976
+7,179
| +7% | +$227K | ﹤0.01% | 1600 |
|
|
2024
Q2 | $3.71M | Buy |
105,797
+9,387
| +10% | +$330K | ﹤0.01% | 1555 |
|
|
2024
Q1 | $4.23M | Buy |
96,410
+10,444
| +12% | +$458K | ﹤0.01% | 1495 |
|
|
2023
Q4 | $3.06M | Buy |
85,966
+7,172
| +9% | +$255K | ﹤0.01% | 1689 |
|
|
2023
Q3 | $2.13M | Buy |
78,794
+1,812
| +2% | +$48.9K | ﹤0.01% | 1822 |
|
|
2023
Q2 | $1.81M | Buy |
76,982
+7,771
| +11% | +$183K | ﹤0.01% | 1966 |
|
|
2023
Q1 | $950K | Buy |
69,211
+5,177
| +8% | +$71.1K | ﹤0.01% | 2149 |
|
|
2022
Q4 | $1.16M | Buy |
64,034
+10,356
| +19% | +$188K | ﹤0.01% | 2050 |
|
|
2022
Q3 | $801K | Buy |
53,678
+3,671
| +7% | +$54.8K | ﹤0.01% | 2263 |
|
|
2022
Q2 | $690K | Buy |
50,007
+10,025
| +25% | +$138K | ﹤0.01% | 2329 |
|
|
2022
Q1 | $447K | Buy |
39,982
+1,835
| +5% | +$20.5K | ﹤0.01% | 2472 |
|
|
2021
Q4 | $902K | Buy |
38,147
+2,887
| +8% | +$68.3K | ﹤0.01% | 2252 |
|
|
2021
Q3 | $899K | Buy |
35,260
+5,889
| +20% | +$150K | ﹤0.01% | 2274 |
|
|
2021
Q2 | $616K | Buy |
29,371
+10,763
| +58% | +$226K | ﹤0.01% | 2464 |
|
|
2021
Q1 | $437K | Buy |
18,608
+1,089
| +6% | +$25.6K | ﹤0.01% | 2553 |
|
|
2020
Q4 | $245K | Buy |
17,519
+3,849
| +28% | +$53.8K | ﹤0.01% | 2758 |
|
|
2020
Q3 | $172K | Buy |
13,670
+324
| +2% | +$4.08K | ﹤0.01% | 2732 |
|
|
2020
Q2 | $190K | Buy |
+13,346
| New | +$190K | ﹤0.01% | 2786 |
|